非糜爛性胃食管反流病應用雷貝拉唑聯合黛力新治療的療效分析

[摘要] 目的 探討非糜爛性胃食管反流病應用雷貝拉唑聯合黛力新治療的效果。方法 隨機收集2014年1月—2016年6月入院的100例非糜爛性胃食管反流病患者隨機分為兩組，對照組患者給予雷貝拉唑治療，實驗組患者則給予雷貝拉唑聯合黛力新治療，比較兩組患者總體治療效果、 GerdQ 評分。結果 實驗組總有效率（94%）較對照組患者總有效率（78%）顯著升高，差異有統計學意義（P< 0.01）；治療前GerdQ 評分（9.03±1.09）實驗組與對照組患者（9.29±1.14）比較，差異無統計學意義（P> 0.05）；治療后，實驗組患者 GerdQ 評分（5.12±1.12）較對照組患者 GerdQ 評分（9.03±1.09）顯著降低，差異有統計學意義（P< 0.01）；實驗組較對照組患者不良反應情況比較，消化道不良反應、神經精神癥狀、藥物過敏反應以及總不良反應率差異無統計學意義（P> 0.05）。結論 不論單用雷貝拉唑還是雷貝拉唑聯合黛力新對非糜爛性胃食管反流病患者都有一定療效，且不良反應發生的情況相近，均較少，但是是雷貝拉唑聯合黛力新對非糜爛性胃食管反流病患者療效更佳， 降低GerdQ 評分更顯著，值得臨床推廣，具有借鑒性。

[關鍵詞] 非糜爛性胃食管反流病；雷貝拉唑；黛力新；療效

[中圖分類號] R571 [文獻標識碼] A [文章編號] 1674-0742（2016）12（b）-0124-04

Analysis of Patients with Non-erosive Gastroesophageal Reflux Disease Rabeprazole Joint Deanxit Treatment

HUANG Hui

Department of Gastroenterology， Ningde Hospital Affiliated to Fujian Medical University， Ningde， Fujian Province ，352100 China

[Abstract] Objective To evaluate the efficacy of rabeprazole in combination with Deanxit in the treatment of non-erosive gastroesophageal reflux disease. Methods Random selection of 100 patients with non-erosive gastroesophageal reflux disease admitted between January 2014 and June 2016 were randomized into two groups. In the control group， rabeprazole was given. In the experimental group， rabeprazole Combined with Deanxit treatment， compared the overall treatment effect of two groups of patients， GerdQ score. Results The total effective rate （94%） of the experimental group was significantly higher than that of the control group （78%）， the difference was statistically significant（P <0.01）； GerdQ score before treatment （9.03 ± 1.09） The GerdQ score in the experimental group was significantly lower than that in the control group （9.29 ± 1.14） （P <0.05）. The GerdQ score （5.12 ± 1.12） in the experimental group was significantly higher than that in the control group （9.03 ± 1.09） （P <0.01）. Compared with the control group， there were no significant difference in adverse reactions， gastrointestinal adverse reactions， neuropsychiatric symptoms， drug allergy reaction and total adverse reaction rate between the experimental group and the control group（P> 0.05）， but the difference was not significant Statistical significance（P> 0.05）. Conclusion Both rabeprazole and rabeprazole combined with deanxitin have certain curative effect on non-erosive gastroesophageal reflux disease， and the adverse reactions are similar， but lesser， Zoloft combined with Deanxit for non-erosive gastroesophageal reflux disease in patients with better efficacy and lower GerdQ score more significant， worthy of clinical promotion， has reference.

[Key words] Non-erosive gastroesophageal reflux disease； Rabeprazole； Deanxit； Efficacy

非糜爛性胃食管反流病也叫NERD，它是指，存在與反流相關的不適癥狀，但通過內鏡下檢查沒有發現明確的食管黏膜破損。其中燒心為主要癥狀，燒心是指胸骨后燒灼樣感覺向咽部或頸部上升[1]。對于GRED來講，通常認為是胃酸等反流人食管，經黏膜破損處接觸并刺激食管黏膜下化學敏感性的痛覺感受器。……